Close Menu

NEW YORK (GenomeWeb) – Invivoscribe Technologies announced today that it has submitted a pre-market approval application with Japan's Pharmaceutical and Medical Devices Agency, as well as a panel track supplement to the US Food and Drug Administration for its LeukoStrat CDx FLT3 Mutation assay.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.